Another form of ILCs studied in ovarian cancer models—the IL-22-producing NKp44– CD56+ TILs, which act as regulatory ILCs—inhibited the outgrowth of tumor-infiltrating CD8+ T-cells, with resulting worse clinical outcomes. Here, CD8A is linked to neoplasm.